GlassScriptPhysician profile
Allan Jay Kogan
NPI 1821136862
$19,896.12
in general payments reported to CMS, 2019-2025
9 companies · $3,940 in 2025
The $3,940 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.95 · 2020: $26.46 · 2022: $2,010 · 2024: $14K · 2025: $3,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Honoraria: $2,428 · Travel and Lodging: $478 · Food and Beverage: $413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,514.50 |
| Honoraria | $2,428.00 |
| Travel and Lodging | $478.37 |
| Food and Beverage | $413.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $5,921.02 | 2024 | |
| Genentech USA, INC. | $4,775.75 | 2024 | Xolair |
| Incyte Corporation | $2,497.50 | 2024 | Opzelura |
| Mckesson Corporation | $2,428.00 | 2024-2025 | |
| Sobi, INC | $2,212.00 | 2025 | |
| Zoll Medical Corporation | $973.33 | 2022 | |
| Olympus Corporation of The Americas | $933.33 | 2022 | |
| Vertos Medical, INC. | $128.73 | 2019-2022 | |
| Eisai INC. | $26.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Kogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.